4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of “Moderate Buy” by Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $47.00.

FDMT has been the topic of several recent analyst reports. Leerink Partners restated an “outperform” rating and set a $36.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Royal Bank of Canada lowered their price objective on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Chardan Capital reaffirmed a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald downgraded 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of FDMT. RA Capital Management L.P. increased its position in 4D Molecular Therapeutics by 21.3% in the first quarter. RA Capital Management L.P. now owns 5,051,511 shares of the company’s stock worth $160,941,000 after purchasing an additional 888,300 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of 4D Molecular Therapeutics by 3.4% during the 1st quarter. Janus Henderson Group PLC now owns 3,197,444 shares of the company’s stock valued at $101,844,000 after buying an additional 104,148 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 25.3% in the 1st quarter. Vanguard Group Inc. now owns 2,339,943 shares of the company’s stock valued at $74,551,000 after acquiring an additional 473,094 shares during the last quarter. State Street Corp grew its position in 4D Molecular Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after acquiring an additional 37,232 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in 4D Molecular Therapeutics by 238.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock worth $16,684,000 after acquiring an additional 1,087,147 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Trading Down 5.8 %

NASDAQ FDMT opened at $8.32 on Tuesday. 4D Molecular Therapeutics has a 12 month low of $7.32 and a 12 month high of $36.25. The stock has a market cap of $384.63 million, a price-to-earnings ratio of -2.92 and a beta of 2.82. The company’s 50 day moving average is $10.17 and its two-hundred day moving average is $16.90.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.